Safety Alerts Saves Lives
Safety Alerts  
 
Home Privacy About Us Contact Us Change Preferences


SafetyAlerts
November 7, 1999

Letter To HealthCare Proffesionals Announce the Withdrawal of RAXAR

Washington, DC (SafetyAlerts) - In a recent letter to healthcare proffessionals, Richard S. Kent, MD, Vice President of US Medical Operations for Glaxo Wellcome has announced the voluntarily withdrawal of all licensed formulations of RAXAR and the product is no longer available from pharmacies.

RAXAR is a fluoroquinolone antibiotic indicated for the treatment of infections caused by strains of bacteria susceptible to grepafloxacin in community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, uncomplicated gonorrhea (urethral in males and endocervical and rectal in females) and non-gonococcal urethritis and cervicitis.

According to the letter, Glaxo Wellcome has recently concluded an extensive review of the safety of RAXAR and determined that due to an effect of RAXAR on cardiac repolarization, manifested as QT interval prolongation on the electrocardiogram (ECG), some patients may be at risk of a very rare but serious ventricular arrhythmia known as torsade de pointes when treated with the product.

Although torsade de pointes has been reported very rarely in patients taking RAXAR, it is considered by the Company that the therapeutic benefit of treatment with RAXAR may be outweighed by the potential risk to patient safety, especially given the availability of alternative treatments.

For patients already commenced on a course of RAXAR, careful consideration should be given to switching the patient to an alternative antibiotic therapy.

If you have any samples of RAXAR in your possession, you may either contact Glaxo Wellcome to request self-addressed, postage-paid boxes to facilitate returning samples to Glaxo Wellcome, or you may dispose of any remaining RAXAR samples in the usual and customary way that you dispose of expired or damaged samples.

If you would like to request boxes, or for more information, please contact the Glaxo Wellcome Customer Response Center at telephone number 1-888-TALK-2-GW (888-825-5249).

Safety Alerts compiles comprehensive safety recall information for the United States. SafeMail is a free email service to warn consumers of faulty products and contaminated foods. For complete information regarding current recalls, past recalls and timely product warning notification visit: www.safetyalerts.com.

Top of Page
(To return - Click Back On Your Browser)